Biovaxys Technology Corp. Closes the Issurer listed for depositing money exemption (life) private placement

Content of the article

Content of the article

On behalf of the board

Content of the article

Content of the article

Warning Statements About How-To Information

Content of the article

This news release includes “forward-looking information” and “forward-looking statements” (collectively “Forward-looking statements“) Within the meaning of applicable securities laws. All statements, including statements of historical fact, without limitation, indicate that they “expect”, “like”, “indicate”, “intend”, or similar statements That events, conditions, or results “will”, “may”, “may”, “or” should “be certain that such statements will occur.

Content of the article

The forward-looking statements reflect the beliefs, opinions and assumptions made on the day mentioned and the estimates, mainly the assumptions made by biovaxys, mainly and the counterfactuals and counterfactuals involved, the risks that biovaxys’ medicines show that they are effective and / or will not receive the necessary regulatory approvals. Regarding the business of Biovaxys, there are many risks that may affect the development of its biotechnology products, caused by the time of clinical approval, the uncertainty that the autolovous cell qugwiniw-the autoloval of the approval of the immunotherapy autolorapy can be developed to produce Safe and effective products and, if so, whether its vaccine products will be accepted in a fragile and profitable manner, liabilities, and protection against infringement of license rights to protect the rights of the price of development and their reliance on third party operations.

Content of the article

Content of the article

A number of factors, both known and unknown, could cause actual results, performance or achievements to differ materially from the results, performance or achievements related to or implied or implied by these assumptions and estimates based on or related to some of these factors. Such factors include, without limitation, the risk that the company does not use the proceeds from the offering as currently expected. Biovaxys does not assume any responsibility to update forward-looking statements, opinions, assumptions, or other material, subject to change, except as required by applicable security laws.

Content of the article

The Canadian Securities Exchange has not reviewed, approved and does not endorse the contents of this news release and accepts no responsibility for the fairness or accuracy of this news release.

Content of the article

Content of the article

Content of the article

Content of the article

View the source version at Businesswire.com:

Content of the article

Content of the article

Content of the article

Content of the article

Content of the article

Content of the article